About Gustav Stålhammar
Associate professor of ophthalmology
Research group leader
M.D. Ph.D. FEBO
Board certified ophthalmologist
Board certified pathologist
My research is focused on predicting and preventing death from ocular tumors.
Uveal melanoma is the most common primary intraocular tumor in adults. Almost half of all patients develop metastases even if the eye has been removed. This is believed to be due to so-called micrometastases that leave the primary tumor very early. These micrometastases can remain dormant in their metastatic niche, including the bone marrow and liver, for several years. Once they leave dormancy and start growing, the patient’s prognosis is poor with a median survival of only 4–15 months. Uveal melanoma is thereby a cancer disease with unpredictable, high mortality and limited treatment options. I would like to help remedy this.
Similarly, I am trying to identify high risk groups and new treatment alternatives for patients with retinoblastoma – the most common intraocular tumor in children, and other ocular and periocular tumors.